Methods for cell mobilization using in vivo treatment with hyaluronan (ha)

Abstract

The use of forms of hyaluronic acid having a molecular weight less than about 750,000 daltons selected from the group consisting of hyaluronic acid and pharmaceutically acceptable salts thereof is provided for the same purposes known for using recombinant GM-CSF or G-CSF.

1 - 243 . (canceled) 
   
   
       244 . A method to facilitate therapeutic kill of cancer cells comprising administering an effective amount of hyaluronic acid prior to administering of an effective amount of a therapeutic agent in a patient suffering from cancer. 
   
   
       245 . The method of  claim 244  wherein the hyaluronic acid is administered at least 1 hour prior to administration of the therapeutic agent. 
   
   
       246 . The method of  claim 244  wherein the hyaluronic acid is administered at least about 4 hours prior to administration of the therapeutic agent. 
   
   
       247 . The method of  claim 244  wherein the hyaluronic acid is administered at least about 24 hours prior to administration of the therapeutic agent. 
   
   
       248 . The method of  claim 244  wherein the patient is administered a priming dose of hyaluronic acid, followed by one or more further doses of hyaluronic acid at daily or weekly intervals, prior to administration of the therapeutic agent by at least 1 hour. 
   
   
       249 . The method of  claim 244  wherein the patient is administered a priming dose of hyaluronic acid, followed by one or more further doses of hyaluronic acid at daily or weekly intervals, prior to administration of the therapeutic agent by at least about 4 hours. 
   
   
       250 . The method of  claim 244  wherein the patient is administered a priming dose of hyaluronic acid, followed by one or more further doses of hyaluronic acid at daily or weekly intervals, prior to administration of the therapeutic agent by at least about 24 hours. 
   
   
       251 . The method of  claim 244  wherein the form of hyaluronic acid is selected from hyaluronic acid and pharmaceutically acceptable salts thereof. 
   
   
       252 . The method of  claim 244  wherein the form of hyaluronic acid is selected from hyaluronic acid and pharmaceutically acceptable salts thereof having a molecular weight less than about 750,000 daltons. 
   
   
       253 . The method of  claim 252  wherein the form of hyaluronic acid is sodium hyaluronate. 
   
   
       254 . The method of  claim 252  wherein the form of hyaluronic acid has a molecular weight of between about 178,000 to about 562,000 daltons. 
   
   
       255 . The method of  claim 252  wherein the form of hyaluronic acid has a molecular weight of about 320,000 daltons. 
   
   
       256 . The method of  claim 252  wherein the form of hyaluronic acid has a molecular weight of 200,000 to 300,000 daltons. 
   
   
       257 . The method of  claim 252  wherein the form of hyaluronic acid has a molecular weight of about 225,000 daltons. 
   
   
       258 . The method of  claim 252  wherein the form of hyaluronic acid has a molecular weight of 25,000 to 100,000 daltons. 
   
   
       259 . The method of  claim 244  wherein hyaluronic acid is administered in an amount effective to promote the release of tissue-localized cancer cells from their tissue attachment. 
   
   
       260 . The method of  claim 244  wherein hyaluronic acid is administered in an amount effective to mobilize cancer cells. 
   
   
       261 . The method of  claim 244  wherein the effective amount of hyaluronic acid is at least about 1.5 mg/kg of body weight. 
   
   
       262 . The method of  claim 244  wherein the effective amount of hyaluronic acid is at least about 3 mg/kg of body weight. 
   
   
       263 . The method of  claim 244  wherein the effective amount of hyaluronic acid is at least about 6 mg/kg of body weight. 
   
   
       264 . The method of  claim 244  wherein the effective amount of hyaluronic acid is at least about 12 mg/kg of body weight. 
   
   
       265 . The method of  claim 248  wherein the priming dose of hyaluronic acid is between 1.5-12 mg/kg of body weight. 
   
   
       266 . The method of  claim 244  wherein multiple cycles of hyaluronic acid administration occur prior to administration of the therapeutic agent. 
   
   
       267 . The method of  claim 244  wherein the cancer cells are of hematopoietic origin. 
   
   
       268 . The methods of  claim 244  wherein the cancer cells are of solid tissue origin. 
   
   
       269 . The method of  claim 244  wherein administration of hyaluronic acid is by injection or infusion. 
   
   
       270 . The method of  claim 244  wherein the therapeutic agent is a chemotherapeutic drug. 
   
   
       271 . The method of  claim 270  wherein hyaluronic acid administration continues during administration of a chemotherapeutic drug. 
   
   
       272 . The method of  claim 244  wherein the therapeutic agent is high dose chemotherapy for cytoreductive kill of cancer cells. 
   
   
       273 . The method of  claim 272  wherein hyaluronic acid administrations continues during high dose chemotherapy. 
   
   
       274 . A method to mobilize cells from a tissue comprising administering single or multiple doses of hyaluronic acid prior to a clinical procedure to decrease the number of the cells in a patient. 
   
   
       275 . The method of  claim 274  wherein the cell is mobilized from the tissue to another tissue. 
   
   
       276 . The method of  claim 274  wherein the cell is a diseased cell or a cell susceptible to disease. 
   
   
       277 . The method of  claim 244  to decrease the number of cancer cells in a lesion or lump, through treatment of patients having a primary cancerous lesion. 
   
   
       278 . The method of  claim 244  to target metastatic or systemic cancers. 
   
   
       279 . The method of  claim 244  wherein the administering begins just after diagnosis. 
   
   
       280 . The method of  claim 244  wherein the administering occurs during a stable phase of the disease. 
   
   
       281 . The method of  claim 244  wherein the administering occurs during periods of partial or complete remission. 
   
   
       282 . The method of  claim 244  wherein the administering occurs at a time of relapse or during disease progression. 
   
   
       283 . The method of  claim 244  wherein the administering occurs in patients thought to be at risk, prior to diagnosis of frank malignancy. 
   
   
       284 . The method of  claim 244  further comprising transplanting autologous or allogeneic hematopoietic cells into the patient.